Targeted mutation of key residues at the start of helix 12 in the hERα ligand-binding domain identifies the role of hydrogen-bonding and hydrophobic interactions in the activity of the protein

Journal of Steroid Biochemistry and Molecular Biology

Volumn 98, Issue 1, 2006, Pages 1-11

  Zhao, Changqing ^a   Abrams, Judith ^a   Skafar, Debra F ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Estrogen; Estrogen receptor; Structure function relationships; Transcription activation

Indexed keywords

4 HYDROXYTAMOXIFEN; AMINO ACID; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; TRANSCRIPTION FACTOR AP 1;

ARTICLE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ESTROGEN RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; HYDROGEN BOND; HYDROPHOBICITY; LIGAND BINDING; MUTATION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING;

BINDING SITES; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HELA CELLS; HUMANS; HYDROGEN BONDING; HYDROPHOBICITY; LIGANDS; MODELS, MOLECULAR; MUTATION; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; RESPONSE ELEMENTS; TAMOXIFEN; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTOR AP-1; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 30944467935     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2005.06.036     Document Type: Article

References (40)

1. R.M. Evans The steroid and thyroid hormone receptor superfamily Science 240 1988 889 895
2. S. Nilsson, and J.-A. Gustafsson Estrogen receptor transcription and transactivation: basic aspects of estrogen action Breast Cancer Res. 2 2000 360 366
3. J.M. Hall, J.F. Couse, and K.S. Korach The multifaceted mechanisms of estradiol and estrogen receptor signaling J. Biol. Chem. 276 2001 36869 36872
4. B.S. Katzenellenbogen, and J.A. Katzenellenbogen Estrogen receptor transcription and transactivation: estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer Breast Cancer Res. 2 2000 335 344
5. G.G. Kuiper, E. Enmark, M. Pelto-Huikko, S. Nilsson, and J.-A. Gustafsson Cloning of a novel receptor expressed in rat prostate and ovary Proc. Natl. Acad. Sci. U.S.A. 93 1996 5925 5930
6. S. Mosselman, J. Polman, and R. Dijkema ER beta: identification and characterization of a novel human estrogen receptor FEBS Lett. 392 1996 49 53
7. P. Webb, P. Nguyen, J. Shinsako, C. Anderson, W. Feng, M.P. Nguyen, D. Chen, S.M. Huang, S. Subramanian, E. McInerney, B.S. Katzenellenbogen, M.R. Stallcup, and P.J. Kushner Estrogen receptor activation function 1 works by binding p160 coactivator proteins Mol. Endocrinol. 12 1998 1605 1618
8. W.J. Gradishar Adjuvant systemic therapy of early stage breast cancer Curr. Treat. Options Oncol. 4 2003 141 150
9. V. Kumar, S. Green, G. Stack, M. Berry, J.R. Jin, and P. Chambon Functional domains of the human estrogen receptor Cell 51 1987 941 951
10. M. Berry, D. Metzger, and P. Chambon Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen EMBO J. 9 1990 2811 2818
11. L. Tora, J. White, C. Brou, D. Tassett, N. Webster, E. Scheer, and P. Chambon The human estrogen receptor has two independent nonacidic transcriptional activation functions Cell 59 1989 477 487
12. M.T. Bocquel, V. Kumar, P. Chambon, and H. Gronemeyer The contribution of the N- and C-terminal regions of steroid receptors to activation of transcription is both receptor and cell-specific Nucleic Acids Res. 17 1989 2581 2595
13. M.T. Tzukerman, A. Esty, D. Santiso-Mere, P. Danielian, M.G. Parker, R.B. Stein, J.W. Pike, and D.P. McDonnell Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions Mol. Endocrinol. 8 1994 21 30
14. E.M. McInerney, and B.S. Katzenellenbogen Different regions in activation function-1 of the human estrogen receptor required for antiestrogen- and estradiol-dependent transcription activation J. Biol. Chem. 271 1996 24172 24178
15. A.M. Brzozowski, A.C.W. Pike, Z. Dauter, R.E. Hubbard, T. Bonn, O. Engstrom, L. Ohman, G.L. Greene, J.-A. Gustafsson, and M. Carlquist Molecular basis of agonism and antagonism in the oestrogen receptor Nature 389 1997 753 758
16. A.K. Shiau, D. Barstad, P.M. Loria, L. Cheng, P.J. Kushner, D.A. Agard, and G.L. Greene The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen Cell 95 1998 927 937
17. M. Gangloff, M. Ruff, S. Eiler, S. Duclaud, J.M. Wurtz, and D. Moras Crystal structure of a mutant hERalpha ligand-binding domain reveals key structural features for the mechanism of partial agonism J. Biol. Chem. 276 2001 15059 15065
18. D.F. Skafar Formation of a powerful capping motif corresponding to start of "helix 12" in agonist-bound estrogen receptor-alpha contributes to increased constitutive activity of the protein Cell Biochem. Biophys. 33 2000 53 62
19. C. Zhao, A. Koide, J. Abrams, S. Deighton-Collins, A. Martinez, J.A. Schwartz, S. Koide, and D.F. Skafar Mutation of Leu-536 in human estrogen receptor-alpha alters the coupling between ligand binding, transcription activation, and receptor conformation J. Biol. Chem. 278 2003 27278 27286
20. F.C. Eng, H.S. Lee, J. Ferrara, R.M. Willson, and J.H. White Probing the structure and function of the estrogen receptor ligand binding domain by analysis of mutants with altered transactivation characteristics Mol. Cell. Biol. 17 1997 4644 4653
21. Z. Chen, B.S. Katzenellenbogen, J.A. Katzenellenbogen, and H. Zhao Directed evolution of human estrogen receptor variants with significantly enhanced androgen specificity and affinity J. Biol. Chem. 279 2004 33855 33864
22. A.S. Levenson, W.H. Catherino, and V.C. Jordan Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor J. Steroid Biochem. Mol. Biol. 60 1997 261 268
23. A.S. Levenson, and V.C. Jordan The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor Cancer Res. 58 1998 1872 1875
24. J.I. Schafer, H. Liu, D.A. Tonetti, and V.C. Jordan The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor Cancer Res. 59 1999 4308 4313
25. S. Anghel, V. Perly, G. Melancon, A. Barsalou, S. Chagnon, A. Rosenauer, W.H. Miller Jr., and S. Mader Aspartate 351 of estrogen receptor alpha is not crucial for the antagonist activity of antiestrogens J. Biol. Chem. 275 2000 20867 20872
26. A.S. Levenson, J.I. MacGregor-Schafer, D.J. Bentrem, K.M. Pease, and V.C. Jordan Control of the estrogen-like actions of the tamoxifen-estrogen receptor complex by the surface amino acid at position 351 J. Steroid Biochem. Mol. Biol. 76 2001 61 70
27. J.A. Schwartz, L. Zhong, S. Deighton-Collins, C. Zhao, and D.F. Skafar Mutations targeted to a predicted helix in the extreme carboxyl-terminal region of the human estrogen receptor-alpha alter its response to estradiol and 4-hydroxytamoxifen J. Biol. Chem. 277 2002 13202 13209
28. S.A. Onate, S.Y. Tsai, M.J. Tsai, and B.W. O'Malley Sequence and characterization of a coactivator for the steroid hormone receptor superfamily Science 270 1995 1354 1357
29. S.A. Onate, V. Boonyaratanakornkit, T.E. Spencer, S.Y. Tsai, M.J. Tsai, D.P. Edwards, and B.W. O'Malley The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors J. Biol. Chem. 273 1998 12101 12108
30. Y. Shang, and M. Brown Molecular determinants for the tissue specificity of SERMs Science 295 2002 2465 2468
31. C.L. Smith, Z. Nawaz, and B.W. O'Malley Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen Mol. Endocrinol. 11 1997 657 666
32. R.M. Lavinsky, K. Jepsen, T. Heinzel, J. Torchia, T.-M. Mullen, R. Schiff, A.L. DelRio, M. Ricote, S. Ngo, J. Gemsch, S.G. Hilsenbeck, C.K. Osborne, C.K. Glass, M.G. Rosenfeld, and D.W. Rose Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes Proc. Natl. Acad. Sci. U.S.A. 95 1998 2920 2925
33. S.T. Pearce, H. Liu, and V.C. Jordan Modulation of estrogen receptor alpha function and stability by tamoxifen and a critical amino acid (Asp-538) in helix 12 J. Biol. Chem. 278 2003 7630 7638
34. G.M. Anstead, K.E. Carlson, and J.A. Katzenellenbogen The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site Steroids 62 1997 268 303
35. S.C. Brooks, and D.F. Skafar From ligand structure to biological activity: modified estratrienes and their estrogenic and antiestrogenic effects in MCF-7 cells Steroids 69 2004 401 418
36. K.E. Weis, K. Ekena, J.A. Thomas, G. Lazennec, and B.S. Katzenellenbogen Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein Mol. Endocrinol. 10 1996 1388 1398
37. R. White, M. Sjoberg, E. Kalkhoven, and M.G. Parker Ligand-independent activation of the oestrogen receptor by mutation of a conserved tyrosine EMBO J. 16 1997 1427 1435
38. Q.X. Zhang, A. Borg, D.M. Wolf, S. Osterreich, and S.A. Fuqua An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer Cancer Res. 57 1997 1244 1249
39. G.B. Tremblay, A. Tremblay, F. Labrie, and V. Giguere Ligand-independent activation of the estrogen receptors alpha and beta by mutations of a conserved tyrosine can be abolished by antiestrogens Cancer Res. 58 1998 877 881
40. M.R. Yudt, D. Vorojeikina, L. Zhong, D.F. Skafar, S. Sasson, T.A. Gasiewicz, and A.C. Notides Function of estrogen receptor tyrosine 537 in hormone binding, DNA binding, and transactivation Biochemistry 38 1999 14146 14156